Drugmakers, insurers, hospitals, pharmacies, medical devices, clinical updates, and healthcare business leaders.
Moderna shares ended the week higher after a session marked by sharp swings, while crypto-related stocks reportedly extended a recent rally in a broader risk-on market tone.
THE APEX TIMES
THE APEX TIMES
Shares of Moderna (MRNA) jumped sharply, while Merck (MRK) and other oncology-adjacent names also rose, after an analyst said perceived success in a Moderna-Merck cancer vaccine effort bodes well for the broader category.
THE APEX TIMES
The remarks, reported by Yahoo Finance, added fresh attention to mRNA platforms in oncology even as Moderna’s shares fell sharply before the open.
THE APEX TIMES
The European regulator has authorized a Tecvayli (teclistamab) and daratumumab combination for patients with relapsed or refractory multiple myeloma, positioning the doublet as a potential new standard of care on the back of Phase 3 results showing statistically significant gains in progression-free survival and overall survival versus standard regimens.
THE APEX TIMES
Moderna said its personalized mRNA cancer therapy intismeran met its primary and key secondary goals in a large Phase 3 melanoma trial. Investors and analysts are left to weigh how much of the potential value is already reflected in the shares and what the next regulatory and commercial steps may require.
THE APEX TIMES
JNJ ended the day down 2.21%, a sharper decline than the broader market as investors pushed healthcare stocks lower.
THE APEX TIMES
A recent market column in Yahoo Finance suggested Moderna’s turnaround is starting to take shape, positioning the company for more than just residual demand from COVID-era products. Details were not provided in the brief market post, leaving investors to look for operational evidence in upcoming company disclosures.
THE APEX TIMES
A new analysis points to an informal “black market” for an Eli Lilly GLP-1 product that is not yet approved, arguing that the demand announcement could intensify pressure across obesity and diabetes treatment rivals.
THE APEX TIMES
Moderna (MRNA) fell sharply in the morning session on Aug. 20 after the stock surged more than 175% the prior session following positive clinical trial news, according to Yahoo Finance.
